Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Oncternal Therapeutics Inc (ONCT)

Oncternal Therapeutics Inc (ONCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Wall Street - NYSE Stock Market American Flag
Stocks Climb Before the Open as Investors Weigh Economic Outlook, U.S. JOLTs Report in Focus Barchart - Tue Apr 4, 2023

June S&P 500 futures (ESM23) are up +0.29%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.61% this morning after three major U.S. benchmark indices finished the regular session mixed as weaker-than-expected...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
TSLA : 248.57 (+0.88%)
VORB : 0.0769 (-34.83%)
OKYO.LN : 1.400 (-24.32%)
BFLY : 0.9776 (-1.58%)
AMC : 5.03 (+0.25%)
ONCT : 6.80 (-4.76%)
EVO : 5.28 (+2.43%)
HLN : 8.46 (unch)
CRBG : 28.71 (-2.18%)
Oncternal Therapeutics, Inc. (ONCT) Q2 2022 Earnings Call Transcript Motley Fool - Wed Aug 10, 2022

ONCT earnings call for the period ending June 30, 2022.

ONCT : 6.80 (-4.76%)
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results Globe Newswire - Tue Aug 9, 2022

Interim Phase 1/2 results for zilovertamab plus ibrutinib in MCL presented at ASCO 2022, with ORR of 85% and CR rate of 41%, compare favorably to...

ONCT : 6.80 (-4.76%)
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results Globe Newswire - Tue Aug 2, 2022

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

ONCT : 6.80 (-4.76%)
Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL Globe Newswire - Thu Jul 14, 2022

Clinical trial collaboration supports global registrational Phase 3 study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab...

ONCT : 6.80 (-4.76%)
Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress Globe Newswire - Fri Jun 10, 2022

SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

ONCT : 6.80 (-4.76%)
Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress Globe Newswire - Fri Jun 10, 2022

SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

ONCT : 6.80 (-4.76%)
Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022 Globe Newswire - Thu Jun 2, 2022

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

ONCT : 6.80 (-4.76%)
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire - Wed Jun 1, 2022

SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

ONCT : 6.80 (-4.76%)
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022 Globe Newswire - Thu May 26, 2022

Updated MCL and CLL data from the CIRLL study are encouraging and continue to improveORR of 85% (23 of 27 evaluable patients) and CR rate of 41% (11 of 27...

ONCT : 6.80 (-4.76%)

Barchart Exclusives

5 Large-Cap Semiconductor Stocks That Outperformed Nvidia in June Barchart - 44 minutes ago
Outperforming Nvidia is quite a feat, especially for its rival large-cap semi stocks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot